Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis.
about
Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide.Current and future pharmacological therapies for NAFLD/NASH.Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency.Hypoxic Signaling and Cholesterol Lipotoxicity in Fatty Liver Disease Progression.Soybean Oil-Derived Poly-Unsaturated Fatty Acids Enhance Liver Damage in NAFLD Induced by Dietary Cholesterol
P2860
Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis.
@ast
Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis.
@en
type
label
Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis.
@ast
Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis.
@en
prefLabel
Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis.
@ast
Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis.
@en
P2093
P2860
P356
P1433
P1476
Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis.
@en
P2093
Kenta Murotani
Kiyoaki Ito
Masashi Yoneda
Norimitsu Ishii
Tadahisa Inoue
Takaya Yamamoto
Tomohiko Ohashi
Yoshitaka Fukuzawa
Yuji Kobayashi
Yukiomi Nakade
P2860
P356
10.1111/HEPR.12887
P577
2017-03-03T00:00:00Z